Bayer’s Jivi approved in Europe for previously treated haemophilia A
November 28, 2018Research and Development, Sales and Marketing Bayer, Jivi, haemophilia, pharma
Bayer has revealed that its recombinant Factor VIII (rFVIII) replacement therapy Jivi, also known as BAY94-9027, has received approval from …
European approval for Takeda’s Alunbrig in ALK+ advanced non-small cell lung cancer
November 27, 2018Research and Development, Sales and Marketing Alunbrig, Cancer, Takeda, lung cancer, pharma
Takeda’s Alunbrig (brigatinib) has been granted marketing approval by the European Commission as a monotherapy to treat anaplastic lymphoma kinase-positive …
Pegfilgrastim greenlight marks eighth biosimilar approval in Europe for Sandoz
November 27, 2018Manufacturing and Production, Sales and Marketing Amgen, Neulasta, Sanofi, Ziextenzo, biosimilars, pegfilgrastim, pharma
The European Commission has chosen to grant marketing authorisation to Ziextenzo, Sandoz’s biosimilar version of pegfilgrastim, better known as Amgen’s …
Phase 3 failure of asthma therapy sends Vectura’s ailing shares falling
November 27, 2018Manufacturing and Production, Research and Development asthma, pharma, trial failure, vectura
Vectura has announced it is terminating development of its severe asthma therapy VR475, an inhaled formulation of the corticosteroid budesonide, …
NHS to save £300 million by switching to Humira biosimilars
November 27, 2018Manufacturing and Production, Sales and Marketing AbbVie, Humira, Mylan, NHS, Sandoz, adalimumab, biosimilars, pharrma
NHS England has announced that the health service is set to save £300 million by switching to biosimilar versions of …
BMS’ Opdivo+Yervoy combo fails in small cell lung cancer
November 27, 2018Manufacturing and Production, Research and Development Bristol-Myers Squibb, Cancer, Yervoy, lung cancer, opdivo, pharma
Bristol-Myers Squibb has revealed that its combo comprising Opdivo (nivolumab) and Yervoy (ipilimumab) failed to meet its primary endpoint as …
FDA approves first oral TRK inhibitor with Loxo Oncology’s Vitrakvi
November 27, 2018Manufacturing and Production, Sales and Marketing Cancer, FDA, Loxo Oncology, Vitrakvi, oncology, pharma
The FDA has announced the approval of the United States’ first-ever oral tyrosine kinase (TRK) inhibitor, Loxo Oncology’s Vitrakvi (larotrectinib), …
European Commission approves first and only long-acting opioid dependence therapy
November 26, 2018Sales and Marketing Europe, opioid crisis, opioids, pharma
Europe has seen its first and only approval of a long-acting therapy for opioid dependence, as the European Commission (EC) …
Sun Pharma’s New Jersey manufacturing overhaul puts 96 jobs at risk
November 26, 2018Manufacturing and Production, Sales and Marketing Sun Pharma, manufacturing, pharma
Indian pharma firm Sun Pharma has announced it is to combine its New Jersey manufacturing operations in a bid to …
Opioid use disorder market to hit $4.8 billion by 2027, says GlobalData
November 26, 2018Sales and Marketing US, opioid crisis, opioids, pharma
New findings released by analytics firm GlobalData indicates that the market for opioid use disorder therapies is set to grow …
Novo Nordisk’s semaglutide meets primary endpoint of reducing cardiovascular events at Phase 3
November 26, 2018Research and Development, Sales and Marketing Novo Nordisk, diabetes, pharma, semaglutide
Novo Nordisk has revealed new Phase 3a data for its investigational GLP-1 analogue therapy semaglutide, showing that the drug met …
Mundipharma’s Neulasta biosimilar approved in EU
November 26, 2018Sales and Marketing Amgen, EU, Europe, Mundipharma, Neulasta, Pelmeg, pharma
Mundipharma has revealed that Pelmeg, its biosimilar version of Amgen’s Neulasta (pegfilgrastim), has been awarded marketing approval by the European …
Top Ten most popular articles on Pharmafile.com this week!
November 23, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kymriah, Mundipharma, UK, US, brexit, pharma, politics, top 10
The appointment of GSK veteran Arnaud Breabout to the position of Senior Vice President and CFO of Mundipharma took the …
Novartis’ gene therapy Luxturna becomes first approved European therapy for vision loss subtype
November 23, 2018Medical Communications, Sales and Marketing EU, Europe, Luxturna, Novartis, pharma, vision loss
Novartis has revealed that its one-time gene therapy Luxturna (voretigene neparvovec) has been awarded approval by the European Commission to …
Immuno Biotech owner promoting unlicensed ‘cure’ for cancer, autism and HIV to be sentenced next week
November 23, 2018Medical Communications Cancer, David Noakes, GcMAF, HIV, UKIP, autism
The owner of Guernsey-based biotech Immuno Biotech Ltd, David Noakes, will be sentenced this week after admitting to a number …
New report finds link between social media and poor mental health among young people
November 23, 2018Medical Communications
Young people between the ages of 11 and 19, living with a mental disorder, were more likely to use social …
NHS hospitals paying 167% more for drugs since 2010/11
November 23, 2018Medical Communications Cost, NHS, UK, hospitals, pricing
Medicines are costing the NHS more than 50% more than a decade ago, while hospitals are paying more than twice …
Pfizer’s Daurismo becomes first of its kind to secure FDA approval in acute myeloid leukaemia
November 22, 2018Research and Development, Sales and Marketing AML, Daurismo, FDA, Pfizer, US, leukaemia
Pfizer has revealed that the FDA has chosen to approve its Daurismo (glasdegib) for the treatment of newly-diagnosed acute myeloid …
Cancer Drugs Fund to offer MSD’s Keytruda for lung cancer
November 22, 2018Sales and Marketing CDF, Cancer, Cancer Drugs Fund, NHS, NICE, UK, keytruda, pharma
MSD’s Keytruda (pembrolizumab) will now be made available via the Cancer Drugs Fund for patients in England, as NICE announces …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
